Cytomedix gets $13M in RDO

Cytomedix says it has landed approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements. The company is developing regenerative therapies for wound care, inflammation and angiogenesis. Cytomedix release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.